The firm also said its partner BioNTech won't exercise its option rights for the CD19- and CD22-directed CAR T-cell therapy candidate AUTO1/22.

The firm is also shuttering its allogeneic cell therapy platform and has tasked a new CEO to lead the company through a merger.

An intravenous form of the gene therapy is already approved and sold as Zolgensma in the US for patients less than 2 years of age.

The firm said that the money will support work with OEM partners and the expanded development and integration of artificial intelligence-based tools.

In a $780 million deal, Servier is obtaining global rights to develop and commercialize BDTX-4933 in multiple solid tumors with RAS or RAF mutations.

The companies have begun integrating Coriell's PGx services into InformedDNA's DNAimpact precision health platform for payors and employers.

The firm's stock price dropped 27 percent on Tuesday following the news that the young man died from acute liver failure after getting Elevidys.

The firm will assess whether adding its CD33-targeted radiotherapy Actimab-A to PD-1 inhibitors will benefit patients more than PD-1 inhibitors alone.

The firm will use the funds to develop its lead candidate in primary hyperoxaluria type 1 and other pipeline products in liver and CNS disorders.

Labor Dr. Wisplinghoff will offer GTC's next-generation sequencing-based tests for solid tumor and hematologic neoplasms.